Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer – guidance (TA683)

NICE recommends pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no EGFR or ALK +ve mutations, only if it is stopped at 2 years of uninterrupted treatment, or earlier

Source:

National Institute for Health and Care Excellence